First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511021-58-00

Acronym

20200469

Enrollment

Registered

2024-08-23

Start date

2022-08-02

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive Stage Small cell lung cancer (ES-SCLC)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Germany, Italy, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026